Enzyme-Linked Immunosorbent Assay (ELISA) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the enzyme-Linked immunosorbent assay (ELISA) market size was valued at USD 2.56 billion in 2025 and is estimated to grow from USD 2.73 billion in 2026 to reach USD 3.78 billion by 2031, at a CAGR of 6.70% during the forecast period (2026-2031).

This report is Segmented by Product Type (Kits & Reagents, Instruments, Software & Services), Assay Technique (Sandwich, Direct, Indirect, Competitive), Application (Diagnostics, Drug Development & Quality Control, Research Use), End User (Hospitals & Clinics, and More), and Geography (North America, Europe, and More ). The Market Forecasts are Provided in Terms of Value (USD).

Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Trends and Insights

Growing prevalence of chronic & infectious diseases

Rising incidences of diabetes, cardiovascular disorders, and persistent viral infections are pushing healthcare providers to embed ELISA into routine population-health programs. National screening agendas in India and China are scaling up biomarker testing volume, with ELISA favored for its validated protocols and low per-test cost, especially when budgets constrain the uptake of newer chemiluminescent systems. Hospital networks in the Middle East are integrating ELISA panels for hepatitis and HIV monitoring within universal-testing rollouts, lifting reagent consumption. Multilateral donors are also financing ELISA-based tuberculosis surveillance in sub-Saharan Africa, enlarging the installed base. The combined effect is a stable sample-volume pipeline that cushions market revenue against cyclical R&D spending patterns.

High-throughput automated ELISA workstations

Automation addresses the chronic shortage of qualified technicians and reduces error rates linked to manual pipetting. Leading platforms now process up to 960 wells per hour with integrated barcode tracking and AI-led result validation, cutting turnaround time by more than 30% for large reference labs. Cost-benefit analyses in US hospital chains show a two-year payback when daily test load exceeds 1,500 samples. European laboratories are layering middleware that feeds results directly into electronic medical records, improving clinical decision efficiency. Asian contract research organizations are adopting lease models that bundle instrumentation, software, and reagents, lowering upfront capital barriers and accelerating penetration.

Cross-reactivity & false positives

Overlap in epitope binding can trigger misleading results, especially when analyte concentration is low or sample matrices are heterogeneous. Clinical laboratories now mandate confirmatory testing for critical biomarkers, adding process steps that inflate operating costs. Regulators responded with tighter validation guidance in 2024, raising the bar for commercial kit launch approvals. Manufacturers counter with high-affinity recombinant antibody pairs and refined blocking buffers, yet performance variability persists among lower-priced kits, complicating procurement decisions for price-sensitive hospitals. The resultant skepticism nudges some institutions toward chemiluminescent formats with broader dynamic range.

Other drivers and restraints analyzed in the detailed report include:

1. Companion diagnostics demand in immuno-oncology
2. Multiplex ELISA panels for immunotherapy monitoring
3. Shift to multiplex bead & CLIA platforms

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Kits & reagents generated 46.95% of the ELISA market in 2025, powered by their recurring-revenue profile and broad menu coverage. Instruments, although representing a smaller installed-base value, are forecast to outpace consumables at a 7.05% CAGR as laboratories pursue automation. The ELISA market size for high-capacity analyzers is expected to reach USD 1.69 billion by 2031, reflecting bundled software and service contracts that lift average selling prices. Vendors now embed cloud analytics for remote calibration and predictive maintenance, shrinking downtime to enhance lab productivity.

Large hospital networks pursue multi-plate robotics that unify microplate washing, incubation, and optical detection, trimming technician hours by up to 40%. Subscription models offer predictable cash flow for suppliers and smoother capital budgeting for customers. Emerging Asian labs, where capital budgets remain constrained, are adopting staged-upgrade pathways: entry-level semi-automated readers today, scalable to full robotics upon volume escalation. Reagent manufacturers collaborate with instrument partners to pre-validate kit compatibility, ensuring plug-and-play deployment and shortening verification cycles.

Sandwich assays still anchor 35.65% of 2025 revenue, preferred for large protein detection owing to dual-antibody specificity. Competitive ELISA, however, expands at 7.28% CAGR as pharmaceutical clients require low-molecular-weight drug quantification during pharmacokinetic studies. Direct ELISA finds traction in rapid toxin screens, while indirect formats remain standard for serological surveillance of emerging pathogens.

Technique selection increasingly hinges on regulatory precedent. Competitive formats enjoy entrenched FDA-cleared protocols for therapeutic drug monitoring, smoothing submission dossiers for new generics. Academic research groups appreciate the technique's tolerance for small antigen targets, fueling catalog diversification among mid-tier kit suppliers. Detection chemistries also evolve: colorimetric substrates give way to amplified fluorescence, extending detection limits and pulling ELISA closer to CLIA performance without overhaul of legacy plate readers.

Geography Analysis

North America generated 41.85% of 2025 revenue and retains leadership through 2031, supported by elevated per-capita healthcare spending and the concentration of top IVD manufacturers. Clinical laboratories readily adopt next-generation instruments, and payors reimburse specialized assays, sustaining premium pricing. Government initiatives to fortify pandemic readiness cement ELISA as a backbone technology within national stockpiles.

Asia-Pacific advances at an 8.12% CAGR, the highest regional pace. China's "Healthy China 2030" blueprint funds hospital immunology labs in secondary cities, lifting capital equipment imports. India's Ayushman Bharat scheme broadens insurance coverage, unlocking rural diagnostic demand met by decentralized ELISA-on-chip devices distributed via primary health centers. Japan and South Korea emphasize automation upgrades, leveraging domestic robotics expertise to raise throughput while offsetting technician shortages; Australia maintains stable demand through public-private pathology partnerships that prioritize assay standardization.

Europe demonstrates balanced growth under the new IVDR that requires higher clinical-evidence thresholds. Germany's manufacturing prowess secures supply chain resilience for regional kit production. The United Kingdom channels Life Sciences Vision funding into oncology biomarker research, inflating competitive ELISA kit usage. Southern European nations roll out EU-supported modernization grants, updating public hospital labs with automated workstations. South America and Middle East & Africa contribute incremental gains as economic headwinds stabilize; multinational NGOs deploy ELISA for surveillance of vector-borne diseases, expanding the installed base that vendors can later monetize with consumables.

1. Thermo Fisher Scientific
2. Danaher Corp. (Beckman Coulter)
3. Roche
4. Merck
5. Bio-Rad Laboratories
6. PerkinElmer
7. Bio-Techne Corp. (R&D Systems)
8. Abcam
9. Agilent Technologies
10. Enzo Biochem
11. Beckton Dickinson
12. Siemens Healthineers
13. QuidelOrtho Corp.
14. Mindray
15. RayBiotech Life, Inc.
16. Eurofins
17. OriGene Technologies
18. Creative Diagnostics
19. Promega
20. Elabscience Biotechnology Co. Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support